Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

Background Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics
(OA), have been found to significantly improve patient outcomes, including reduced …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Aims: To examine medication adherence and discontinuation in two separate groups of
patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting …

Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

Medication nonadherence in schizophrenia can have serious implications including
relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer …

Aim Results from clinical trials support the use of oral antipsychotics for treatment of early or
first‐episode psychosis in patients with schizophrenia. This paper will review literature on …

Schizophrenia and related disorders remain major disabling conditions, mainly due to
antipsychotic treatment resistance and to relapses related to antipsychotic nonadherence …

Introduction Understanding patients' preferences for long-acting injectable (LAI) or oral
antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia …

Opinion Statement Schizophrenia is a mostly chronic mental disorder, and symptomatic
relapse is frequently observed. It is often associated with social and/or occupational decline …